Expression of mutant p53 protein in hepatocellular carcinoma

Gut

Volumn 35, Issue 1, 1994, Pages 98-100

  Collier, J D ^a   Carpenter, M ^a   Burt, A D ^a   Bassendine, M F ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UNITED KINGDOM;

EID: 0028117354     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.35.1.98     Document Type: Article

References (32)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
2. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40 transformed cells. Nature 1979; 278: 261-3.
3. Reich NC, Levine AJ. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 1984; 308: 199-201.
4. Mercer WE, Nelson D, DeLeo AB, Old LJ, Baserga R. Microinjection of monoclonal antibody to p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci USA 1982; 79: 6309-12.
5. Hinds PW, Finlay CA, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63: 739-46.
6. Hinds PW, Finlay CA, Quarbin RS, Baker SJ, Fearon GR, Vogelstein B et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ 1990; 1: 571-80.
7. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-602.
8. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
9. Ozturk M, Bressac B, Puisleux A, Kew M, Volkmann M, Bozcall S, et al. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991; 338: 1356-9.
10. Foster PL, Eisenstadt E, Miller JH. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci USA 1983; 80: 2695-8.
11. Challen C, Lunec J, Warren W, Collier J, Bassendine MF. Analysis of the p53 tumour suppressor gene in human hepatocellular carcinomas from Britain. Hepalology 1992; 12: 1362-6.
12. Kress S, Jahn U-R, Buchmann A, Bannasch P. Schwarz M. p53 mutations in human hepatocellular carcinomas from Germany. Cancer Res 1992; 52: 3220-3.
13. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim D, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1233-8.
14. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-703.
15. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of human p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-44.
16. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
17. Hsu IC, Metcalf RA, Sun T, Welch JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-8.
18. Hosono S, Lee C-S, Chou M-J, Yang C-S, Shih C. Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines. Oncogene 1991; 6: 237-43.
19. Scorsone KA, Zhou Y-Z, Butel JS, Slagle BL. p53 mutations cluster at codon 249 in Hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 1992; 52: 1635-8.
20. Oren M, Maltzman W, Levine AJ. Post translocational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol; 1: 101-10.
21. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms a hsc 70 - p53 complex with an altered half life. Mol Cell Biol 1988; 8: 531-9.
22. Werness BA, Levine AJ, Howley PM. Association of human papilloma virus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.
23. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51: 4090-6.
24. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992; 340: 259-63.
25. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893-9.
26. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
27. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88: 5006-10.
28. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87: 7555-9.
29. Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 1990; 87:4766-70.
30. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 1992; 52: 3674-8.
31. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859-86.
32. Laurent-Puig P, Flejou J-F, Fabre M, Bedossa P, Belghiti J, Gayral F et al. Overexpression of p53: a rare event in a large series of white patients with hepatocellular carcinoma. Hepatology 1992; 16: 1171-5.